BR112017011808A2 - Methods for the development and use of minimally polarized functional micro-aggregate units of cells in tissue applications using lgr4, lgr5 and lgr6 that express epithelial stem cells - Google Patents

Methods for the development and use of minimally polarized functional micro-aggregate units of cells in tissue applications using lgr4, lgr5 and lgr6 that express epithelial stem cells

Info

Publication number
BR112017011808A2
BR112017011808A2 BR112017011808-4A BR112017011808A BR112017011808A2 BR 112017011808 A2 BR112017011808 A2 BR 112017011808A2 BR 112017011808 A BR112017011808 A BR 112017011808A BR 112017011808 A2 BR112017011808 A2 BR 112017011808A2
Authority
BR
Brazil
Prior art keywords
composition
tissue
further characterized
aggregate
cellular
Prior art date
Application number
BR112017011808-4A
Other languages
English (en)
Portuguese (pt)
Inventor
M. LOUGH Denver
Original Assignee
Polarityte, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56078499&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112017011808(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Polarityte, Inc. filed Critical Polarityte, Inc.
Publication of BR112017011808A2 publication Critical patent/BR112017011808A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N1/00—Preservation of bodies of humans or animals, or parts thereof
    • A01N1/10—Preservation of living parts
    • A01N1/12—Chemical aspects of preservation
    • A01N1/122—Preservation or perfusion media
    • A01N1/125—Freeze protecting agents, e.g. cryoprotectants or osmolarity regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • A61L27/362—Skin, e.g. dermal papillae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/38—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells
    • A61L27/3804—Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix containing added animal cells characterised by specific cells or progenitors thereof, e.g. fibroblasts, connective tissue cells, kidney cells
    • A61L27/3813—Epithelial cells, e.g. keratinocytes, urothelial cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Dermatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Environmental Sciences (AREA)
  • Dentistry (AREA)
  • Botany (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112017011808-4A 2014-12-02 2015-12-01 Methods for the development and use of minimally polarized functional micro-aggregate units of cells in tissue applications using lgr4, lgr5 and lgr6 that express epithelial stem cells BR112017011808A2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462086526P 2014-12-02 2014-12-02
US62/086,526 2014-12-02
US14/954,335 2015-11-30
US14/954,335 US10926001B2 (en) 2014-12-02 2015-11-30 Methods related to minimally polarized functional units
PCT/US2015/063114 WO2016089825A1 (en) 2014-12-02 2015-12-01 Methods for development and use of minimally polarized function cell micro-aggregate units in tissue applications using lgr4, lgr5 and lgr6 expressing epithelial stem cells

Publications (1)

Publication Number Publication Date
BR112017011808A2 true BR112017011808A2 (en) 2018-02-27

Family

ID=56078499

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017011808-4A BR112017011808A2 (en) 2014-12-02 2015-12-01 Methods for the development and use of minimally polarized functional micro-aggregate units of cells in tissue applications using lgr4, lgr5 and lgr6 that express epithelial stem cells

Country Status (21)

Country Link
US (7) US10926001B2 (cg-RX-API-DMAC7.html)
EP (2) EP3227431B1 (cg-RX-API-DMAC7.html)
JP (3) JP6791854B2 (cg-RX-API-DMAC7.html)
KR (5) KR20210043024A (cg-RX-API-DMAC7.html)
CN (1) CN107250348B (cg-RX-API-DMAC7.html)
AU (3) AU2015355187C1 (cg-RX-API-DMAC7.html)
BR (1) BR112017011808A2 (cg-RX-API-DMAC7.html)
CA (1) CA2969707C (cg-RX-API-DMAC7.html)
CO (1) CO2017006640A2 (cg-RX-API-DMAC7.html)
CR (1) CR20170296A (cg-RX-API-DMAC7.html)
EA (1) EA201791125A1 (cg-RX-API-DMAC7.html)
GB (2) GB2569056B (cg-RX-API-DMAC7.html)
HK (1) HK1250515A1 (cg-RX-API-DMAC7.html)
IL (2) IL252613B (cg-RX-API-DMAC7.html)
MX (2) MX2017007243A (cg-RX-API-DMAC7.html)
MY (1) MY184931A (cg-RX-API-DMAC7.html)
NZ (2) NZ733433A (cg-RX-API-DMAC7.html)
PH (1) PH12017501009B1 (cg-RX-API-DMAC7.html)
SG (2) SG10201914058QA (cg-RX-API-DMAC7.html)
WO (1) WO2016089825A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201703907B (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110913690A (zh) * 2017-03-14 2020-03-24 朱诺治疗学股份有限公司 用于低温储存的方法
CA3088129A1 (en) * 2018-01-26 2019-08-01 Polarityte, Inc. Composite-interfacing biomaterial accelerant substrate
WO2019148143A1 (en) * 2018-01-26 2019-08-01 Polarityte, Inc. Complex living interface-coordinated self-assembling materials (clicsam)
FR3082123B1 (fr) 2018-06-07 2020-10-16 Urgo Rech Innovation Et Developpement Pansement cellularise et son procede de fabrication
JP2024006681A (ja) * 2022-07-04 2024-01-17 学校法人近畿大学 生体材料
WO2025166131A1 (en) * 2024-02-01 2025-08-07 Board Of Regents, The University Of Texas System Compositions and methods for treating bone and muscle injuries

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040126881A1 (en) * 2002-09-06 2004-07-01 Vincent Ronfard Fibrin cell supports and methods of use thereof
WO2006008009A2 (en) 2004-07-23 2006-01-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with leucine-rich repeat-containing gpcr 6 (lgr6)
US20060154365A1 (en) 2004-08-30 2006-07-13 Anthony Ratcliffe Cultured three dimensional tissues and uses thereof
US8053559B2 (en) 2005-10-27 2011-11-08 Coloplast A/S Biodegradable scaffold with ECM material
US20100328320A1 (en) 2006-07-13 2010-12-30 Kerstna Juergen Medical information management in a patient information hub system
US8366723B2 (en) 2006-08-03 2013-02-05 Rassman Licensing, Llc Hair harvesting device and method with localized subsurface dermal fluid insertion
WO2008031767A1 (en) 2006-09-12 2008-03-20 Dkfz Deutsches Krebsforschungszentrum, Stiftung Des Öffentlichen Rechts Cell culture of keratinocytes under non-differentiating conditions
EP2412800A1 (en) 2010-07-29 2012-02-01 Koninklijke Nederlandse Akademie van Wetenschappen Liver organoid, uses thereof and culture method for obtaining them
GB201111244D0 (en) 2011-06-30 2011-08-17 Konink Nl Akademie Van Wetenschappen Knaw Culture media for stem cells
US9752124B2 (en) 2009-02-03 2017-09-05 Koninklijke Nederlandse Akademie Van Wetenschappen Culture medium for epithelial stem cells and organoids comprising the stem cells
FI20095355A0 (fi) 2009-04-01 2009-04-01 Helsingin Yliopisto Regeneroituva aktiivinen matriisi ja sen käytöt
JP2012531185A (ja) 2009-06-25 2012-12-10 株式会社 資生堂 Aff‐4を指標とした抗白髪剤のスクリーニング方法
US20110130711A1 (en) 2009-11-19 2011-06-02 Follica, Inc. Hair growth treatment
US20130101564A1 (en) 2010-06-30 2013-04-25 Jinxi Chen Method for preparing dermis tissue cells aggregation and uses thereof
GB201106395D0 (en) 2011-04-14 2011-06-01 Hubrecht Inst Compounds
JP6215216B2 (ja) 2011-10-27 2017-10-18 ウニヴェルジテート ライプチッヒ 毛包外毛根鞘からメラノサイトを誘導する方法および移植のための調製
JP6186997B2 (ja) 2012-08-07 2017-08-30 日油株式会社 塗布型帯電防止剤
US9655930B2 (en) 2012-10-01 2017-05-23 Aderans Research Institute, Inc. Compositions and methods for producing reconstituted skin
US20140106447A1 (en) 2012-10-12 2014-04-17 Mimedx Group, Inc. Compositions and methods for recruiting stem cells
BR112015023261A2 (pt) 2013-03-14 2017-07-18 Massachusetts Inst Technology composições e métodos para expansão e cultura de células-tronco epiteliais
US9592257B2 (en) 2013-10-11 2017-03-14 MWV Cell, LLC Complete human skin organ generated from culture-expanded cells
CN103550828B (zh) * 2013-10-17 2016-01-27 中国科学院动物研究所 一种基于毛囊干细胞和硅凝胶敷料的皮肤重建方法
TWI548413B (zh) 2014-11-07 2016-09-11 國立臺灣大學 誘導毛囊新生的皮膚萃取物、組合物及其用途

Also Published As

Publication number Publication date
CR20170296A (es) 2018-01-25
EP3227431B1 (en) 2025-01-29
US11266765B2 (en) 2022-03-08
WO2016089825A1 (en) 2016-06-09
EP3227431A4 (en) 2019-01-02
AU2019240603B2 (en) 2023-02-09
GB201902819D0 (en) 2019-04-17
GB2549872A (en) 2017-11-01
GB201710646D0 (en) 2017-08-16
US20160151540A1 (en) 2016-06-02
PH12017501009A1 (en) 2017-12-11
US20190046691A1 (en) 2019-02-14
US20220241464A1 (en) 2022-08-04
AU2023202857A1 (en) 2023-05-25
KR20190111167A (ko) 2019-10-01
US11338060B2 (en) 2022-05-24
US20180154044A1 (en) 2018-06-07
NZ755260A (en) 2021-12-24
IL287488B2 (en) 2023-06-01
AU2015355187B2 (en) 2019-10-03
EP3227431A1 (en) 2017-10-11
CA2969707A1 (en) 2016-06-09
AU2015355187C1 (en) 2020-02-20
EP4438128A2 (en) 2024-10-02
US12465669B2 (en) 2025-11-11
EP4438128A3 (en) 2024-11-13
CN107250348A (zh) 2017-10-13
JP2020182880A (ja) 2020-11-12
AU2015355187A1 (en) 2017-06-29
HK1245327A1 (zh) 2018-08-24
SG10201914058QA (en) 2020-03-30
US10926001B2 (en) 2021-02-23
AU2019240603A1 (en) 2019-10-17
MX2017007243A (es) 2018-01-25
MY184931A (en) 2021-04-30
MX2023001655A (es) 2023-04-24
JP2017538411A (ja) 2017-12-28
HK1250515A1 (zh) 2018-12-21
GB2569056A (en) 2019-06-05
US11000629B2 (en) 2021-05-11
US20230181797A1 (en) 2023-06-15
CA2969707C (en) 2019-08-20
EP3227431C0 (en) 2025-01-29
CO2017006640A2 (es) 2017-11-21
EA201791125A1 (ru) 2018-06-29
US20210322643A1 (en) 2021-10-21
CN107250348B (zh) 2021-09-03
KR20210043024A (ko) 2021-04-20
US20180154043A1 (en) 2018-06-07
JP6791854B2 (ja) 2020-11-25
ZA201703907B (en) 2023-03-29
GB2569056B (en) 2020-01-01
IL287488A (en) 2021-12-01
NZ733433A (en) 2019-08-30
JP2019088299A (ja) 2019-06-13
US11596714B2 (en) 2023-03-07
PH12017501009B1 (en) 2022-01-21
KR20180136587A (ko) 2018-12-24
IL252613B (en) 2021-12-01
KR20170098844A (ko) 2017-08-30
SG11201704502RA (en) 2017-06-29
KR20180136588A (ko) 2018-12-24
IL252613A0 (en) 2017-07-31

Similar Documents

Publication Publication Date Title
JOP20230167A1 (ar) مساعدات مستقبل gpcr، وتركيبات صيدلانية تشتمل عليها، وطرق استخدامها
AR127117A2 (es) Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores
CL2019000431A1 (es) Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. (divisional solicitud 201700814)
BR112016029582A2 (pt) derivados de exendina-4 como agonistas de receptor de glucagon seletivos
PH12017501009B1 (en) Methods for development and use of minimally polarized function cell micro-aggregate units in tissue applications using lgr4, lgr5 and lgr6 expressing epithelial stem cells
MX2015000990A (es) Analogos del glucagon.
MX2015014408A (es) Co-agonista de peptido similar a glucagon tipo 1 (glp-1) receptor de glucagon de larga duracion, estables para uso medico.
CR20210036A (es) Tratamiento contra el cáncer de útero
ECSP15014941A (es) Compuestos antivíricos para el vsr
CO2017004932A2 (es) Métodos para seleccionar una línea de células t y donador de la misma para terapia celular adoptiva
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
CR20160117A (es) Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos
CL2012001539A1 (es) Anticuerpo 005-c04 que antagonizan la señalizacion mediada por el receptor de prolactina; secuencia de acido nucleico que codifica dicho anticuerpo; vector de expresion y célula huesped que comprenden dicha secuencia de acido nucleico; uso del anticuerpo para terapia hormonal combinada; composicion farmacéutica que comprende el anticuerpo.
CL2017000053A1 (es) Anticuerpos de unión a protofibrillas aß
CL2017002407A1 (es) Péptidos y combinación de péptidos novedosos para su uso en inmunoterapia contra diversos tumores
CL2015002692A1 (es) Novedosos compuestos de bencenosulfonamida, método para sintetizarlos y uso de los compuestos en medicina y en cosméticos.
PH12018501237A1 (en) Isoindole compounds
MX2019005160A (es) Formulacion farmaceutica.
MX2016010215A (es) Composiciones y metodos de tratamiento y prevencion de degeneracion macular.
PH12019500949A1 (en) Ror-gamma modulators
MX368735B (es) (r)-pirlindol y sus sales farmaceuticamente aceptables para uso en medicina.
BR112016008288A2 (pt) receptor fc gama solúvel para tratamento de doenças autoimunes bolhosas
EA201691596A1 (ru) Составы гепарина для наружного применения
BR112016024510A2 (pt) ?medicamento, uso de brexpiprazol ou de um sal farmaceuticamente aceitável do mesmo, métodos para prevenção ou tratamento de um transtorno relacionado com substância e para produção de uma composição farmacêutica, composição farmacêutica, e, kit?
AR096092A1 (es) ANTICUERPOS ANTI-IGF-1R CON ABOLICIÓN DE LA UNIÓN AL FcRn Y SU UTILIZACIÓN EN EL TRATAMIENTO DE ENFERMEDADES OCULARES VASCULARES

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: ARQUIVADO O PEDIDO DE PATENTE, NOS TERMOS DO ARTIGO 86, DA LPI, E ARTIGO 14 DA PORTARIA 52/2023, REFERENTE AO NAO RECOLHIMENTO DA 11A RETRIBUICAO ANUAL.PARA FINS DE RESTAURACAO CONFORME ARTIGO 87, DA LPI 9.279, E ARTIGO 15, DA PORTARIA 52/2023, O DEPOSITANTE DEVERA, NO PRAZO DE 3 (TRES) MESES, PROCE-DER COM:? PAGAMENTO DA GRU SERVICO 208, REFERENTE A TAXA DE RESTAURACAO DO PE-DIDO.? PAGAMENTO DE1 (UMA) GRU, SERVICO 221, REFERENTE(S) A(S) ANUIDADE(S) EM QUESTAO, NO VALOR EXTRAORDINARIO, CONFORME TABELA VIGENTE, SEGUNDO O ART. 84O 2O DA LEI NO 9.279/96.CASO NAO HAJA PAGAMENTO CONJUNTO, DENTRO DO PRAZO LEGAL, DAS RETRIBUICOES SUPRACITADAS, SERA MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, AT